Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Accesswire
All objectives evaluating DehydraTECH™ drug delivery platform successfully achievedKELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps.Lexaria's objectives in its 2021 antiviral drug examination program thus far have been to determine whether:DehydraTECH processing of compounds from leading classes of antiviral drugs for SARS-CoV-2/COVID-19, HIV/AIDS and other infectious diseases could exhibit evidence of superior oral absorption relative to controls,DehydraTECH processing of those compounds would preserve expected viral inhibitory performance upon efficacy testing in infected mammalian cells, andDehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities that could be challenging to guide through the regulatory approv
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study [Yahoo! Finance]Yahoo! Finance
- Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 StudyAccesswire
- Lexaria Awarded New Patents [Yahoo! Finance]Yahoo! Finance
- Lexaria Awarded New PatentsAccesswire
- Lexaria to Present at The LD Micro Invitational XIV [Yahoo! Finance]Yahoo! Finance
LEXX
Analyst Actions
- 3/5/24 - Maxim Group
LEXX
Sec Filings
- 4/25/24 - Form SC
- 4/24/24 - Form 8-K
- 4/9/24 - Form 10-Q
- LEXX's page on the SEC website